Hoth Therapeutics Receives USPTO Filing Receipt for HT-001 Formulation Patent Application, Expanding Existing Patent Coverage

Core Insights - Hoth Therapeutics, Inc. has received an official Filing Receipt from the USPTO for a new patent application related to HT-001, its lead clinical asset [1][3] - The new patent application aims to expand the company's intellectual property portfolio and protect the unique formulation and delivery method of HT-001, which is designed to alleviate dermatologic side effects in cancer patients undergoing EGFR inhibitor therapy [2][3] Company Overview - Hoth Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments to improve patient quality of life [4] - The company emphasizes a patient-centric approach and collaborates with scientists, clinicians, and key opinion leaders to explore therapeutics with significant potential [4]